Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| DMAE (Dimethylaminoethanol) | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 150-400 mg/day (as DMAE bitartrate, typically 37% DMAE) | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning. With or without food. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Ongoing; no strict cycling required | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Structural analog of choline that crosses the BBB more readily than choline itself. Paradoxically increases choline availability not by serving as a direct precursor to acetylcholine, but by inhibiting choline metabolism in peripheral tissues, thereby increasing circulating choline available for brain uptake. Also acts as a free radical scavenger and membrane stabilizer. Reduces lipofuscin accumulation in neuronal cells, an age pigment associated with cellular aging.
150-400 mg/day (as DMAE bitartrate, typically 37% DMAE)
Morning. With or without food.
Ongoing; no strict cycling required
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →